



Small Molecules

- October 2023 -

Small Molecule Funding - October 2023 By Amount Raised (1 of 2)

Total financings for category exceeded \$854M (17% of total), across 13 deals.

Date	Company	Investment Cluster	Modality	About	Investment (\$M)	Round	Investors
10-16	Nuvalent	Boston	Small Molecule	Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer.	\$300.00	Post IPO Equity	
10-20	Abivax	Europe	Small Molecule	Abivax develops medicines that alter the body's natural immune system mechanisms.	\$236.00	IPO	
10-27	IDEAYA Biosciences	San Francisco	Small Molecule	IDEAYA is a precision medicine oncology company with deep research and development expertise in synthetic lethality.	\$143.80	Post IPO Equity	Public Offering
10-05	AstronauTx	Europe - UK	Small Molecule	AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes.	\$61.00	Series A	Novartis Venture Fund, MPM Capital, Brandon Capital, EQT Life Sciences, Bristol Myers Squibb and the Dementia Discovery Fund
10-31	Nykode Therapeutics	Europe	Small Molecule	Clinical-stage biopharmaceutical platform that develops novel vaccines against HPV-induced malignancies	\$45.00	Undisclosed	
10-17	Amplifier Therapeutics	New York	Small Molecule	Amplifier Therapeutics is a biopharmaceutical firm, developing AMP-activated protein kinase (AMPK) activator molecules.	\$33.30	Series A	Future Ventures, Cambrian Biopharma, RA Capital Management

Small Molecule Funding - October 2023 By Amount Raised (2 of 2)

Date	Company	Investment Cluster	About	Investment (\$M)	Round	Investors
10-13	Zenshine Pharma	China	Zenshine Pharma is a clinical-stage biopharmaceutical company with a focus on small molecule drugs for cancer and autoimmune diseases.	\$13.70	Series C	Zhonghui Investment, Saizhi Bole, Kunlun Capital, Jumpcan
10-31	Palatin Technologies, Inc.	New Jersey	biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system	\$5.00	Post IPO Equity	Direct Offering
10-19	Purple Biotech	Israel	a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance.	\$5.00	Post IPO Equity	
10-31	SELLAS Life Sciences	New York	a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications	\$4.00	Post IPO Equity	Institutional Investor
10-20	iQure Pharma	New Jersey	iQure Pharma is a global biotech company that develops new therapeutics for patients and physicians.	\$1.50	Venture	Ventura Biomed and OKG Capital
10-24	Ocean Biomedical	Rhode Island	biopharma company with an innovative business model that accelerates the development and commercialization of scientifically compelling assets from research universities and medical centers.	\$1.00	Grant	Falk Award